Medications · Hormone optimization

Estradiol

Bioidentical estrogen for hormone replacement.

Start a prescription All medications →
Estradiol molecular structure (Bioidentical estrogen)

Why this needs to be personal

Why Personalized Estradiol

The FDA-approved estradiol products were built around averages: a patch that releases roughly 0.05 mg per day, a gel pump that delivers a fixed metered dose, an oral tablet at 0.5, 1, or 2 mg. Those strengths were calibrated for symptom relief in trial populations, not for your baseline estradiol level, your uterine status, your VTE history, your skin's response to patch adhesives, the specific vasomotor or genitourinary symptoms you are still having on a commercial dose, or whether you are receiving feminizing therapy that needs serum levels the menopausal product line was never designed to produce.

That is what compounding adds. The molecule is the same 17-beta-estradiol the FDA reviewed; what changes is the delivery. A transdermal cream can be made at a strength that sits between two commercial gel doses. A vaginal preparation can be made without the propylene glycol or paraben preservatives a patient reacts to. A subcutaneous pellet can be prepared at a strength no FDA-approved estradiol pellet provides, because no FDA-approved estradiol pellet exists in the US. A feminizing-therapy patient can be dosed to a target serum estradiol outside the menopausal label range. Each of these is a patient-specific prescription written by a licensed prescriber, prepared for that named patient, dispensed after pharmacist review.

This is the older arrangement, the one that predates mass-manufactured tablets and metered gels. A clinician writes the order, a pharmacist prepares the preparation for that patient, the label carries the patient's name. Modern state inspection, USP standards, and recall infrastructure keep it honest.

In brief

Estradiol Explained

Estradiol is the main estrogen hormone your body makes, ovaries produce most of it before menopause, with smaller amounts coming from fat tissue and the adrenals 37. After menopause, ovarian estradiol falls sharply, and that drop drives hot flashes, night sweats, vaginal dryness and painful sex, sleep disruption, and accelerated bone loss.

Doctors prescribe estradiol to relieve those menopausal symptoms, protect bone in selected patients, and, for transgender women and gender-diverse people, as the principal hormone in feminizing therapy 37361. The FDA has approved many estradiol products: pills (Estrace), skin patches (Climara, Vivelle-Dot, Minivelle), gels (Divigel, EstroGel, Elestrin), a topical spray (Evamist), vaginal creams and tablets (Estrace Cream, Vagifem), vaginal rings (Estring, Femring), a low-dose vaginal softgel (Imvexxy), and long-acting injections (Delestrogen, Depo-Estradiol).

RonanRx compounds bioidentical estradiol when a patient needs something the manufactured products do not provide, a custom transdermal cream strength, an allergen-free vehicle, a pellet (no FDA-approved estradiol pellet exists in the US), vaginal preparations at non-commercial doses, or feminizing-therapy doses for gender-affirming care. The 2020 National Academies report 43 criticized broad marketing claims that compounded bioidentical hormones are safer or more 'natural' than FDA-approved products, RonanRx does not make those claims 44. Estradiol is contraindicated in pregnancy, in women with a history of estrogen-sensitive cancer, and in those with prior venous thromboembolism; transdermal and vaginal routes carry lower clot risk than oral 20 17.

At a glance

Quick Facts About Estradiol

Category
Endogenous estrogen (bioidentical steroid hormone)
Active ingredient
17β-estradiol (bioidentical), also esterified as estradiol valerate, estradiol cypionate, and estradiol hemihydrate in various commercial products
FDA-approved branded products
Numerous: Estrace (oral and vaginal cream), Climara / Vivelle-Dot / Minivelle / Alora (transdermal patch), Divigel / Elestrin / EstroGel (transdermal gel), Estrasorb (topical emulsion), Estring / Femring (vaginal ring), Vagifem / Yuvafem (vaginal tablet), Imvexxy (vaginal softgel insert), Delestrogen (IM estradiol valerate), Depo-Estradiol (IM estradiol cypionate)
Routes studied in humans
Oral, transdermal (patch / gel / spray / cream), vaginal (cream / tablet / ring / softgel), intramuscular (valerate, cypionate), subcutaneous pellet (compounded)
Evidence posture
FDA-approved manufactured products are well-studied; landmark trials include WHI (Rossouw 2002; Anderson 2004), ELITE (Hodis 2016), KEEPS (Miller 2019; Gleason 2015), the WHIMS cognition substudies, and the E3N cohort on route- and progestogen-specific breast cancer risk
FDA-approval status
Multiple FDA-approved manufactured products for vasomotor symptoms, moderate-to-severe vulvovaginal atrophy / dyspareunia, hypoestrogenism, prevention of postmenopausal osteoporosis, and (in oncology) palliation of advanced breast and prostate cancer. Compounded variants are not FDA-approved but address patient-specific needs (custom strengths, allergen-free vehicles, pellets, gender-affirming dosing) the manufactured market does not provide.
Compounded under
503A, patient-specific prescription only
Compounded role
Patient-specific compounding addresses needs the manufactured market does not meet: custom transdermal cream strengths between commercial gel doses; allergen-free formulations for patients with patch-adhesive reactions; subcutaneous pellets (no FDA-approved estradiol pellet exists in the US, Testopel is testosterone only); vaginal estradiol at non-commercial concentrations; and gender-affirming feminizing doses outside approved product labels. NASEM 2020 explicitly criticized broad cBHRT marketing claims, and RonanRx does not endorse them; compounding is justified by documented patient-specific clinical need.
Schedule
Not a controlled substance. Pregnancy category X, contraindicated in pregnancy.

Prescription review

Patient-Specific Prescription Only

Estradiol on this page is a 503A compounded preparation. Every dose is made on a prescription, for a named patient, by a licensed pharmacist. It is not a stocked, mass-manufactured product.

  • Made to order, not off a shelf. No batch sits in a warehouse waiting for buyers. Your prescription is what triggers the prep.
  • Named-patient label. The bottle carries your name. The batch records carry your prescription.
  • Dose, strength, and route chosen for you. A prescriber who knows your chart decides what gets compounded, not a manufacturer who set the strength for a trial population.
  • Licensed pharmacist on the hook. A real person, with a license that can be pulled, signs off on every prep. State inspectors check the facility.
  • Compounded drugs are not FDA-approved. They should not be evaluated using branded-drug trial data. Availability varies by state and prescribed medication.
For prescribing doctors Offer this medication → For patients Find a partner clinic →

Real medicine, not gray market

How This Differs from a Research-Use-Only Website

A research-use-only website ships a vial from a warehouse. There is no prescription, no pharmacist, no facility inspection, and no way to recall the product if something is wrong with it. If the vial is mislabeled, contaminated, or under-potent, there is nobody whose license is at stake.

A 503A compounding pharmacy is the other thing. Your doctor writes the prescription. A licensed pharmacist, whose name is on the label, prepares the medicine in a facility the state inspects. If something goes wrong, there is a person and a license on the hook, and a documented chain of custody on every lot. That accountability is what makes it safe.

What it is

What is Estradiol?

Estradiol (17β-estradiol; 1,3,5(10)-estratrien-3,17β-diol) is the principal endogenous estrogen in humans 36. In premenopausal women, granulosa cells of the developing ovarian follicle produce most circulating estradiol from androgenic precursors via the aromatase enzyme (CYP19A1). Smaller amounts come from peripheral aromatization of androgens in adipose tissue, bone, brain, and skin. In men, estradiol arises mainly from peripheral aromatization of testosterone and contributes to bone, lipid, and reproductive physiology.

Bioidentical estradiol, the same chemical entity as endogenous human estradiol, has been available pharmaceutically since the 1930s, when Doisy isolated crystalline estrone and estradiol from urine and Inhoffen synthesized estradiol from cholesterol 36. Replacement therapy has been in continuous use since the 1940s, initially with conjugated equine estrogens and increasingly with bioidentical estradiol in oral, transdermal, vaginal, intramuscular, and pellet forms.

The molecule itself is delivered in many forms: oral micronized estradiol; transdermal patches, gels, sprays, and emulsions; vaginal creams, tablets, softgel inserts, and rings; intramuscular ester depots (estradiol valerate, estradiol cypionate); and, exclusively as compounded preparations in the US, subcutaneous pellets. Each formulation is a different solution to the same delivery challenge: producing physiologic serum or local-tissue estradiol exposure while managing the first-pass hepatic effects on coagulation and binding globulins that drive much of estradiol's route-specific safety profile 20, 23 36.

How it works

How Estradiol Works

Class
Bioidentical estrogen
First studied
1933 (synthesis)
Common forms
Cream, troche, suppository, capsule
Compounding category
503A, patient-specific prescription

Estradiol acts at two nuclear estrogen receptors, ERα and ERβ, expressed in reproductive tract, breast, bone, brain, cardiovascular tissue, liver, and adipose. Ligand binding triggers receptor dimerization, nuclear translocation, and transcription of estrogen-responsive genes. ERα predominates in uterus, mammary epithelium, and liver; ERβ predominates in vascular endothelium, lung, prostate, and parts of the central nervous system. Beyond classical genomic signaling, estradiol also activates membrane-associated estrogen receptors (GPER and membrane-localized ERα) that drive rapid, nongenomic signaling through MAPK, PI3K/Akt, and nitric oxide synthase cascades.

Replacement therapy raises serum estradiol toward the premenopausal physiologic range, with downstream effects on vasomotor stability, vaginal and urethral epithelium, bone resorption (estradiol suppresses osteoclast activity), lipid metabolism, mood, and cognition. The Endocrine Society 36 and NAMS 37 frame these effects as the basis for the established menopausal symptom and osteoporosis-prevention indications. The 'timing hypothesis' 17, that estradiol's vascular effects depend on when after menopause therapy starts, is supported by ELITE's carotid intima-media thickness data showing benefit when therapy was initiated within 6 years of menopause but not after 10+ years.

Importantly, exogenous estradiol in the absence of a progestogen causes endometrial proliferation and increases the risk of endometrial hyperplasia and adenocarcinoma in women with an intact uterus. This is why estradiol monotherapy is contraindicated in women with an intact uterus and why combined estradiol-plus-progestogen regimens are standard in that population. The PEPI trial 15 characterized this endometrial-protective role of cyclic and continuous progestogen across regimens, while bone-density benefit was maintained.

Research history

Estradiol Research History

Estradiol was isolated and characterized in the 1930s. Doisy isolated crystalline estrone from pregnancy urine in 1929 and crystalline estradiol from sow ovaries in 1935; Inhoffen and Hohlweg synthesized estradiol from cholesterol in 1938. Doisy shared the 1943 Nobel Prize in Physiology or Medicine for the discovery of vitamin K, with his estrogen work cited among his major contributions. Oral and parenteral estradiol preparations entered clinical use through the 1940s, with conjugated equine estrogens (Premarin, FDA-approved in 1942) becoming the dominant prescription form for several decades.

Transdermal delivery emerged in the 1980s with the Estraderm reservoir patch, providing the first route that avoided first-pass hepatic metabolism. Matrix patches (Climara, Vivelle, Vivelle-Dot, Minivelle, Alora) and transdermal gels (EstroGel, Divigel, Elestrin) followed in the 1990s and 2000s, each refining adhesion, dosing flexibility, and serum-level stability. Vaginal estradiol preparations expanded from the long-standing creams (Estrace Cream, Premarin Cream) to low-dose tablets (Vagifem; ultra-low 10 microgram dosing), rings (Estring for local effect, Femring for systemic effect), and a low-dose vaginal softgel (Imvexxy, FDA-approved 2018) 30, 32.

The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial in the 1990s 15 established the bone-density benefit of postmenopausal estrogen across regimens and the endometrial-protective role of progestogen co-therapy in women with an intact uterus. The Estrogen in the Prevention of Atherosclerosis Trial (EPAT) 16 was an early randomized controlled study suggesting estradiol slowed carotid intima-media thickness progression in postmenopausal women not previously treated for coronary disease.

The Women's Health Initiative (WHI), the largest randomized hormone-therapy program ever conducted, fundamentally reshaped clinical practice. The combined CEE + medroxyprogesterone acetate arm was stopped early in 2002 1 for an excess of breast cancer plus modest increases in coronary heart disease, stroke, and venous thromboembolism that crossed a pre-specified global safety index. The estrogen-alone (CEE in hysterectomized women) arm continued through 2004 2 and showed a different risk profile, with reduced breast cancer incidence. The Manson 2013 4 follow-up and the Manson 2017 18-year cumulative analysis 3 confirmed no excess all-cause mortality in either arm during the extended follow-up.

Substudies refined the picture. WHIMS 9, 10, 11 reported excess dementia and global cognitive decline in women aged 65+ on CEE ± MPA. WHIMS-Y 12 later examined younger women. Bone outcomes were favorable for combined therapy 6. Stefanick 2006 7 showed reduced mammographic abnormalities and breast cancer in the CEE-alone arm. Cushman 2004 13 quantified the VTE excess on combined therapy. Pradhan 2002 14 characterized inflammatory biomarker changes.

Post-WHI, the field re-evaluated WHI's relevance to younger, recently menopausal women, the population for whom hormone therapy is now most commonly recommended. KEEPS 18 randomized recently menopausal women to oral conjugated equine estrogens, transdermal estradiol, or placebo for 4 years; arterial imaging surrogates were neutral but symptom and bone effects favored active therapy. KEEPS-Cog 19 showed no cognitive harm with hormone therapy initiated near menopause, in contrast to the WHIMS signal in older women. ELITE 17 randomized women stratified by time since menopause and reported less carotid intima-media thickness progression on oral estradiol when initiated within 6 years of menopause, but not when initiated 10+ years out, the most direct test of the 'timing hypothesis.' Salpeter 2006 27 and Salpeter 2009 28 meta-analyses had earlier suggested that younger women initiating therapy near menopause had lower coronary and all-cause mortality.

Route-specific safety became a major theme. The French ESTHER case-control study 20, the population-based Renoux study 22, the QResearch / CPRD nested case-control 23, and a systematic review and meta-analysis 24 consistently reported lower VTE risk with transdermal versus oral estrogen. The E3N cohort 25 reported that micronized progesterone and dydrogesterone, when paired with estradiol, produced lower breast cancer risk than synthetic progestins. The Million Women Study 26 reported elevated breast cancer risk with combined therapy across regimens.

Vaginal and local estradiol preparations were studied separately. The Cochrane review of local vaginal estrogen 29 established the efficacy of vaginal estrogen across formulations for genitourinary syndrome of menopause. The TX-004HR (Imvexxy) trials 30, 31 supported the low-dose vaginal softgel. Mitchell 2018 33 compared vaginal estradiol tablets, moisturizer, and placebo in postmenopausal women with bothersome vulvovaginal symptoms. Bhupathiraju 2018 34 and Crandall 2018 35 examined chronic disease outcomes in long-term vaginal estrogen users.

Gender-affirming feminizing therapy uses estradiol as the principal hormone. The Endocrine Society 2017 guideline 38 and WPATH Standards of Care Version 8 39 define current best practice for estradiol dosing, monitoring, and shared decision-making in transgender women and gender-diverse people. Estradiol valerate IM, estradiol cypionate IM, transdermal estradiol patches, oral estradiol, and (in compounded practice) subcutaneous pellets are all used in this population.

The 2020 National Academies of Sciences, Engineering, and Medicine consensus report on compounded bioidentical hormone therapy 43 reviewed the clinical utility, safety, and marketing of compounded hormones. It found insufficient evidence to support broad claims of safety or efficacy advantages over FDA-approved manufactured products and recommended restricting compounded preparations to documented patient-specific clinical needs, the framework RonanRx follows.

Timeline

Estradiol Timeline

  1. 1929 Doisy isolates crystalline estrone (theelin) from pregnancy urine, first pure isolation of a human estrogen
  2. 1935 Doisy isolates crystalline estradiol from sow ovaries
  3. 1938 Inhoffen and Hohlweg synthesize estradiol from cholesterol, basis for industrial pharmaceutical production
  4. 1942 FDA approves Premarin (conjugated equine estrogens), dominant prescription estrogen for several decades
  5. 1986 FDA approves Estraderm, the first transdermal estradiol patch, establishes the non-oral route that avoids first-pass hepatic metabolism
  6. 1996 PEPI trial reports bone-density preservation with postmenopausal estrogen across regimens and endometrial-protective effect of progestogen co-therapy 15
  7. 2001 Hodis et al publish the Estrogen in the Prevention of Atherosclerosis Trial (EPAT) in Annals of Internal Medicine, early randomized evidence that oral estradiol slows carotid intima-media thickness in postmenopausal women without prior CHD 16
  8. 2002 Writing Group for the Women's Health Initiative publishes the principal results of the combined CEE + MPA trial in JAMA, trial stopped early for excess breast cancer, CHD, stroke, and VTE crossing the global safety index 1
  9. 2003 Manson et al publish WHI estrogen plus progestin and coronary heart disease in NEJM; Cauley et al publish bone-fracture results in JAMA; Beral et al publish Million Women Study breast cancer results in Lancet; Rapp et al publish WHIMS global cognitive results in JAMA 562611
  10. 2004 Anderson et al publish WHI CEE-alone (hysterectomy) results in JAMA, different risk profile from combined arm, with reduced breast cancer incidence; Shumaker and Espeland publish WHIMS dementia and cognition substudies in JAMA; Cushman publishes WHI VTE substudy in JAMA 291013
  11. 2006 Stefanick et al publish WHI CEE-alone breast cancer and mammography results in JAMA; Suckling et al publish Cochrane review of local vaginal estrogen for vaginal atrophy 729
  12. 2006 Salpeter et al publish meta-analysis suggesting reduced coronary heart disease events on hormone therapy in younger women initiating therapy near menopause 27
  13. 2007 Canonico et al publish ESTHER case-control study in Circulation, transdermal estradiol carries lower VTE risk than oral; progestogen type also matters 20
  14. 2008 Fournier et al publish E3N cohort breast cancer results in Breast Cancer Research and Treatment, estradiol plus micronized progesterone or dydrogesterone carried lower breast cancer risk than estradiol plus synthetic progestins 25
  15. 2009 Salpeter et al publish Bayesian meta-analysis of hormone therapy and mortality in younger postmenopausal women in American Journal of Medicine 28
  16. 2010 Renoux et al publish population-based study of HRT and VTE risk in Journal of Thrombosis and Haemostasis, confirms route differential 22
  17. 2011 Files, Ko, and Pruthi publish 'Bioidentical hormone therapy' in Mayo Clinic Proceedings, widely cited critical review of the bioidentical-hormone marketing landscape 40
  18. 2013 Manson et al publish WHI health outcomes during intervention and extended poststopping phases in JAMA; Vaughan et al publish WHIMS-Y baseline characteristics in Brain Research 412
  19. 2015 Gleason et al publish KEEPS-Cog results in PLoS Medicine, no cognitive harm with hormone therapy initiated near menopause, contrasting WHIMS in older women; Stuenkel et al publish Endocrine Society 2015 menopause guideline in JCEM; Boardman et al publish Cochrane review of hormone therapy for cardiovascular disease prevention; Mohammed et al publish JCEM meta-analysis of oral vs transdermal estrogen vascular events 19364124
  20. 2016 Hodis et al publish ELITE in NEJM, oral estradiol initiated within 6 years of menopause slowed carotid intima-media thickness progression; not so when initiated 10+ years out, strongest randomized support of the timing hypothesis 17
  21. 2017 Manson et al publish 18-year cumulative WHI mortality analysis in JAMA, no excess all-cause or cause-specific mortality in either WHI arm during extended follow-up; Constantine and Kingsberg publish TX-004HR (Imvexxy) trial data; Hembree et al publish Endocrine Society guideline on endocrine treatment of gender-dysphoric/gender-incongruent persons in JCEM 3303138
  22. 2018 FDA approves Imvexxy (estradiol vaginal softgel insert); Mitchell et al publish vaginal estradiol vs moisturizer vs placebo RCT in JAMA Internal Medicine; Bhupathiraju and Crandall analyze long-term vaginal estrogen safety in NHS and WHI 32333435
  23. 2019 Miller et al publish KEEPS overview ('what have we learned') in Menopause; Vinogradova et al publish QResearch / CPRD nested case-control of HRT and VTE in BMJ, confirms route differential at scale 1823
  24. 2020 National Academies of Sciences, Engineering, and Medicine publish 'The Clinical Utility of Compounded Bioidentical Hormone Therapy' consensus report, finds insufficient evidence for broad safety/efficacy claims over FDA-approved products and recommends restricting compounded preparations to documented patient-specific clinical needs 43
  25. 2022 NAMS publishes the 2022 Hormone Therapy Position Statement in Menopause, current consensus framework for menopausal hormone therapy; Coleman et al publish WPATH Standards of Care Version 8 3739

Natural role

Biological Role of Estradiol

Estradiol is the principal mediator of female sexual development and adult reproductive physiology. During puberty in females, it drives breast development, uterine and vaginal maturation, the pubertal growth spurt, epiphyseal closure, and adult bone-density accrual. In adult premenopausal women, cyclical estradiol secretion from the developing ovarian follicle drives endometrial proliferation in the follicular phase, the mid-cycle LH surge that triggers ovulation, and physiologic preparation of cervical mucus and vaginal epithelium for reproduction.

Beyond reproduction, estradiol has major effects on bone (suppression of osteoclastic resorption, the abrupt loss of estradiol at menopause drives the acute postmenopausal phase of bone loss), cardiovascular tissue (vasodilation, favorable lipid effects, endothelial nitric oxide signaling), the central nervous system (mood, cognition, thermoregulation, the loss of estradiol-driven thermoregulatory tone underlies vasomotor symptoms), and the urogenital tract (epithelial maturation, mucus production, urethral function) 36.

Estradiol is also a normal physiologic hormone in men, where it derives mainly from aromatization of testosterone in adipose tissue, bone, and brain. The Finkelstein 2013 gonadal-suppression study established that a substantial fraction of testosterone's effects on bone density, fat mass, and some sexual function in men is mediated by aromatization to estradiol rather than by testosterone itself, establishing that estradiol is a physiologic hormone in male biology, not just a side effect of high testosterone exposure 3715.

Clinical contexts studied

Clinical Contexts for Estradiol

Moderate-to-severe vasomotor symptoms of menopause fda approved

FDA-approved indication across the oral, transdermal, and systemic-dose vaginal-ring estradiol product range.

Estradiol is FDA-approved for moderate-to-severe vasomotor symptoms (hot flashes, night sweats) due to menopause. The Endocrine Society 2015 guideline 36 and NAMS 2022 Position Statement 37 frame systemic estradiol (with progestogen in women with an intact uterus) as the most effective therapy for moderate-to-severe vasomotor symptoms in appropriate candidates initiating therapy within 10 years of menopause and under age 60. The Cochrane review of long-term hormone therapy 42 and the Boardman 2015 Cochrane review of hormone therapy for cardiovascular disease prevention 41 provide the systematic-review framing.

Branded product: Estrace, Climara, Vivelle-Dot, Minivelle, Divigel, EstroGel, Elestrin, Femring, Delestrogen, Depo-Estradiol

Moderate-to-severe vulvovaginal atrophy / genitourinary syndrome of menopause fda approved

FDA-approved indication for vaginal estradiol products.

Vaginal estradiol, creams, tablets, softgels, and rings, is FDA-approved for moderate-to-severe vulvovaginal atrophy and dyspareunia due to menopause 32. The Cochrane review 29, the TX-004HR (Imvexxy) trials 30, 31, the JAMA Internal Medicine RCT comparing vaginal estradiol tablets, moisturizer, and placebo 33, and the long-term safety analyses in NHS 34 and WHI 35 together provide a strong evidence base for local vaginal estrogen. Systemic absorption is minimal at recommended doses, and observational data support a favorable safety profile.

Branded product: Estrace Cream, Vagifem, Yuvafem, Imvexxy, Estring, Premarin Cream

Prevention of postmenopausal osteoporosis fda approved

FDA-approved indication for systemic estradiol in appropriate candidates.

Systemic estradiol is FDA-approved for prevention of postmenopausal osteoporosis in women at significant risk and for whom non-estrogen therapies are unsuitable. The PEPI trial 15 established bone-density preservation across CEE-based regimens; WHI 6 confirmed reduced hip and clinical fractures with combined therapy in older women. Current NAMS 37 and Endocrine Society 36 framing positions estradiol as a reasonable bone-preserving choice for symptomatic women within 10 years of menopause, with non-estrogen alternatives preferred when osteoporosis is the sole indication in older women given WHI's broader risk profile in that age stratum.

Branded product: Climara, Vivelle-Dot, Minivelle, Estrace

Hypoestrogenism (primary ovarian insufficiency, surgical menopause, hypopituitarism) fda approved

FDA-approved indication for systemic estradiol.

Estradiol replacement is FDA-approved and clinically standard for hypoestrogenism due to primary ovarian insufficiency, bilateral oophorectomy, or hypogonadotropic hypogonadism, with goals of preserving bone density, ameliorating vasomotor symptoms, and supporting cardiovascular health to physiologic-age expectations. The Endocrine Society guideline 36 and NAMS 2022 37 frame this population as a clear long-duration indication, distinct from age-typical menopausal hormone therapy decisions.

Branded product: Estrace, Climara, Vivelle-Dot, Divigel, EstroGel

Cardiovascular safety and the 'timing hypothesis' well studied

Addressed by ELITE, KEEPS, and WHI subgroup analyses.

The 'timing hypothesis', that initiating estradiol near menopause produces a different cardiovascular risk/benefit profile than initiating it a decade later, is supported by ELITE 17 for carotid intima-media thickness, by KEEPS 18 for symptom and surrogate endpoints, and by the WHI age-stratified reanalyses. The Boardman 2015 Cochrane review 41 integrates the randomized evidence base. Hodis EPAT 16 was an early supporting RCT. Salpeter 2006 27 and 2009 28 meta-analyses suggested reduced CHD events and lower all-cause mortality in younger initiators. Route also matters: transdermal estradiol carries lower VTE and stroke risk than oral in observational data 20, 23, 24, 22.

Breast cancer risk on estradiol-based hormone therapy well studied

Well-studied; risk depends on regimen, route, progestogen, and time since menopause.

WHI 1 reported elevated invasive breast cancer on CEE + medroxyprogesterone in older women, but the CEE-alone arm in hysterectomized women 2, 7 showed reduced breast cancer incidence. The E3N cohort 25 reported that micronized progesterone or dydrogesterone, paired with estradiol, produced lower breast cancer risk than estradiol plus synthetic progestins. The Million Women Study 26 reported elevated breast cancer risk with combined therapy across regimens. Long-term WHI follow-up 8, 3 refined the cumulative incidence and mortality picture across the two regimens. The current consensus 37 frames breast cancer risk as a function of regimen (combined > estrogen-alone), progestogen type (synthetic progestins > micronized progesterone), duration, and baseline risk.

Cognition and dementia risk well studied

Time-of-initiation dependent; WHIMS in older women showed harm; KEEPS-Cog and WHIMS-Y do not show harm in younger initiators.

WHIMS 9, 10 reported excess probable dementia and global cognitive decline on CEE ± MPA in women aged 65+. Rapp 2003 11 reported the global cognitive function findings in JAMA. WHIMS-Y 12 examined younger women. KEEPS-Cog 19 randomized recently menopausal women and reported no cognitive harm, and possible mood benefit, over 4 years of oral or transdermal therapy. The current consensus 37 positions hormone therapy as not indicated for cognitive protection but acceptable from a cognition-safety standpoint in symptomatic recently menopausal women.

Off-label use

Off-Label Uses of Estradiol

Gender-affirming feminizing hormone therapy well studied

Standard-of-care per Endocrine Society and WPATH guidelines; no estradiol product carries this specific FDA indication.

Estradiol is the principal hormone of feminizing hormone therapy in transgender women and gender-diverse people. The Endocrine Society 2017 guideline 38 and WPATH Standards of Care Version 8 39 define current best practice for estradiol dosing (oral, transdermal patch, transdermal gel, sublingual, IM valerate or cypionate, and compounded pellet), monitoring (serum estradiol and total testosterone, with co-administered anti-androgen as appropriate), and shared decision-making. RonanRx compounded estradiol is dispensed in this context only on a patient-specific prescription from the patient's clinician; this page does not substitute for those guidelines.

Compounded bioidentical hormone therapy (cBHRT) emerging

Not recommended as broadly safer or more effective than FDA-approved products per NASEM 2020 and NAMS.

Marketing of compounded bioidentical hormone therapy as broadly safer, more 'natural,' or more effective than FDA-approved products is not supported by the evidence base reviewed in the 2020 National Academies consensus report 43 37. NASEM recommended restricting compounded preparations to documented patient-specific clinical needs, allergen sensitivity, dose customization, alternative routes, and not as a general-purpose substitute for FDA-approved products. The Files 2011 Mayo Clinic Proceedings review 40 articulated the same critique earlier. RonanRx follows this framework: compounded estradiol is dispensed for documented patient-specific reasons, not as a marketing claim of superiority.

Palliative therapy in advanced prostate cancer (high-dose estradiol) emerging

Historically used as androgen-suppression; largely replaced by GnRH analogues. Mentioned here for completeness only.

High-dose oral estrogens (diethylstilbestrol, ethinyl estradiol) were a historical mainstay of androgen-deprivation therapy in advanced prostate cancer through the 1970s. The cardiovascular and VTE burden led to their replacement by GnRH analogues and antagonists. Transdermal estradiol has been studied in this context as a route that may avoid the first-pass hepatic coagulation burden of oral estrogens. This page focuses on menopausal and feminizing indications; prostate-cancer hormonal therapy is outside the typical 503A compounding context for estradiol 36.

FDA-approved use

FDA-Approved Uses of Estradiol

BrandIndicationYearRoute
Estrace (oral) Vasomotor symptoms, vulvovaginal atrophy, hypoestrogenism, prevention of postmenopausal osteoporosis 1975 Oral micronized estradiol tablet
Estrace Cream Moderate-to-severe vulvovaginal atrophy — Vaginal cream (0.01% estradiol)
Climara Vasomotor symptoms, vulvovaginal atrophy, hypoestrogenism, prevention of postmenopausal osteoporosis 1994 Transdermal patch (weekly)
Vivelle-Dot / Vivelle Vasomotor symptoms, vulvovaginal atrophy, hypoestrogenism, prevention of postmenopausal osteoporosis 1999 Transdermal patch (twice weekly)
Minivelle Vasomotor symptoms, prevention of postmenopausal osteoporosis 2012 Transdermal patch (twice weekly)
Alora Vasomotor symptoms, vulvovaginal atrophy, hypoestrogenism, prevention of postmenopausal osteoporosis 1996 Transdermal patch (twice weekly)
Divigel Moderate-to-severe vasomotor symptoms 2007 Transdermal gel sachet
EstroGel Moderate-to-severe vasomotor symptoms, vulvovaginal atrophy 2004 Transdermal gel pump
Elestrin Moderate-to-severe vasomotor symptoms 2006 Transdermal gel pump
Estrasorb Moderate-to-severe vasomotor symptoms 2003 Topical emulsion
Evamist Moderate-to-severe vasomotor symptoms 2007 Transdermal spray
Vagifem / Yuvafem Moderate-to-severe vulvovaginal atrophy / atrophic vaginitis 1999 Vaginal tablet (10 microgram)
Imvexxy Moderate-to-severe dyspareunia due to vulvar and vaginal atrophy 2018 Vaginal softgel insert (4 or 10 microgram)
Estring Moderate-to-severe urogenital symptoms of postmenopausal atrophy 1996 Vaginal ring (low-dose, local effect)
Femring Moderate-to-severe vasomotor and vulvovaginal symptoms 2003 Vaginal ring (systemic dose)
Delestrogen Vasomotor symptoms, hypoestrogenism, palliation of advanced breast cancer, palliation of advanced prostate cancer — Intramuscular estradiol valerate in oil
Depo-Estradiol Vasomotor symptoms, hypoestrogenism — Intramuscular estradiol cypionate in oil

Numerous FDA-approved estradiol products are available across oral, transdermal patch, transdermal gel and spray, vaginal cream and tablet and ring and softgel insert, and intramuscular ester routes. Approved indications across the product range include moderate-to-severe vasomotor symptoms of menopause, moderate-to-severe vulvovaginal atrophy and dyspareunia (vaginal products), prevention of postmenopausal osteoporosis in appropriate candidates, hypoestrogenism due to primary ovarian insufficiency or castration, and, for selected IM products, palliation of advanced estrogen-responsive breast cancer and advanced prostate cancer 30.

The Endocrine Society 2015 guideline 36 and NAMS 2022 Hormone Therapy Position Statement 37 frame the diagnostic and prescribing standard. Compounded estradiol preparations are not FDA-approved; they are dispensed under 503A on a patient-specific prescription when the manufactured product range does not meet a documented clinical need 30.

Compounded use

Compounded Estradiol (503A)

Compounded estradiol occupies a meaningful 503A niche, distinct from typical 'essentially-a-copy' compounding 40. The manufactured market is broad but not exhaustive: it offers oral micronized estradiol at limited strengths, transdermal patches and gels at fixed strengths, vaginal preparations at fixed local doses, and IM esters at fixed concentrations. The manufactured market does not offer FDA-approved estradiol pellets, the only marketed pellet product (Testopel) is testosterone, so any estradiol pellet preparation in US practice is inherently compounded.

Patient-specific compounding addresses needs the manufactured market does not provide: custom transdermal cream strengths between commercial gel doses, allergen-free formulations for patients who react to patch adhesives or to specific gel vehicles, subcutaneous pellets at clinician-specified doses, vaginal estradiol at non-commercial concentrations (for example, ultra-low-dose preparations below Vagifem's 10 microgram strength or above for selected refractory atrophy), and gender-affirming feminizing-therapy doses that fall outside the labeled ranges of approved menopausal products 38, 39 40.

Per FDA guidance on compounded copies of approved drugs 44, the prescribing clinician documents the patient-specific clinical reason 40. For estradiol the documented reasons are typically formulation/route the manufactured market does not provide (pellet, custom transdermal cream strength), allergen/excipient sensitivity (alternative vehicle), strength outside the manufactured range, or gender-affirming-care dosing outside the menopausal label. Routine substitution of compounded for manufactured product without a documented reason is not the appropriate framing.

The 2020 NASEM report on compounded bioidentical hormone therapy 43 explicitly criticized broad marketing claims that compounded estradiol is safer, more effective, or more 'natural' than FDA-approved bioidentical estradiol, claims that conflate the molecule (which is identical) with the manufacturing pathway 4037. RonanRx does not endorse those marketing claims. Compounded estradiol is bioidentical to FDA-approved estradiol; the case for compounding is a patient-specific clinical need, not a superiority claim.

Formulations and routes

Estradiol Formulations and Routes

FormConcentrationDescription
Oral micronized estradiol tablet Manufactured: 0.5, 1, 2 mg (Estrace); compounded capsules at custom strengths Daily oral dosing. Extensive first-pass hepatic conversion to estrone produces a higher E1:E2 ratio than non-oral routes. Hepatic exposure drives SHBG induction and the higher VTE and stroke risk seen with oral versus transdermal estrogen in observational data.
Transdermal patch Manufactured: 0.025, 0.0375, 0.05, 0.075, 0.1 mg/day (Climara, Vivelle-Dot, Minivelle, Alora) Weekly or twice-weekly application. Avoids first-pass hepatic metabolism; serum estradiol and metabolite profile approximate premenopausal physiologic. Patch-adhesive reactions in some patients motivate compounded alternatives.
Transdermal gel or spray Manufactured: Divigel 0.25, 0.5, 0.75, 1.0 mg/sachet; EstroGel 0.06%; Elestrin 0.06%; Evamist 1.53 mg/spray; compounded creams at custom percentages Daily application. Like patches, avoids first-pass. Custom compounded transdermal creams provide strengths between commercial pump doses; useful for titration.
Vaginal cream Manufactured: Estrace Cream 0.01%; compounded creams at custom strengths Intravaginal application for genitourinary syndrome of menopause. Local effect on vaginal epithelium, urethra, and bladder trigone. Systemic absorption is dose-dependent; recommended low-dose regimens produce minimal systemic exposure.2933
Vaginal tablet or softgel insert Manufactured: Vagifem 10 microgram; Yuvafem 10 microgram; Imvexxy 4 or 10 microgram softgel Low-dose intravaginal release for vulvovaginal atrophy. Imvexxy supported by TX-004HR clinical program.303132
Vaginal ring Estring (low-dose, local effect, 7.5 microgram/day for 90 days); Femring (systemic dose, 0.05 or 0.1 mg/day for 90 days) Three-month intravaginal ring. Estring delivers a local dose with minimal systemic exposure; Femring delivers a systemic dose that treats both genitourinary and vasomotor symptoms.
Intramuscular estradiol ester in oil Delestrogen 10, 20, 40 mg/mL (estradiol valerate); Depo-Estradiol 5 mg/mL (estradiol cypionate); compounded variants at custom concentrations Long-acting depot for systemic estradiol. Commonly used in gender-affirming feminizing therapy and in selected menopausal contexts where other routes are not feasible. Peak-trough serum estradiol variability over the dosing interval is wider than with transdermal continuous delivery.
Subcutaneous estradiol pellet (compounded) Custom, typical 12.5, 25, 37.5, 50 mg per pellet, often co-implanted with testosterone pellet in selected practice Implanted in the subcutaneous fat of the hip or buttock; releases estradiol over 3, 6 months. No FDA-approved estradiol pellet exists in the United States, Testopel is testosterone only, so any estradiol pellet preparation is inherently compounded. The published safety and pharmacokinetic evidence for estradiol pellets is limited; long-term outcome data are largely observational from specialty pellet-therapy clinics.
Sublingual / troche (compounded) Custom, typical 0.5, 2 mg per troche Sublingual or buccal slow-dissolve troche. Bypasses first-pass metabolism with rapid absorption and peak serum estradiol within 1, 2 hours; trough levels fall within 6, 8 hours. Used by some clinicians for menopausal symptoms or gender-affirming feminizing therapy.

Routes used in published literature: oral, transdermal, topical, vaginal, intramuscular, subcutaneous, sublingual, buccal, troche.

Dosing

Estradiol Dosing

RoutePopulationRangeDurationStudy type
Oral Postmenopausal women, vasomotor symptoms or osteoporosis prevention Estradiol 0.5, 2 mg orally once daily; with progestogen co-therapy in women with an intact uterus (typically micronized progesterone 100, 200 mg/day or cyclic 200 mg for 12, 14 days/month) Typically reassessed annually; lowest effective dose for the shortest duration consistent with treatment goals Endocrine Society 2015 guideline; NAMS 2022 Position Statement3637
Transdermal patch Postmenopausal women, vasomotor symptoms or osteoporosis prevention 0.025, 0.1 mg/day; weekly (Climara) or twice-weekly (Vivelle-Dot, Minivelle, Alora) application; with progestogen co-therapy in women with an intact uterus Reassessed annually; route preferred over oral when VTE / stroke risk concerns are present FDA-labeled regimens; route-specific safety supported by ESTHER (Canonico 2007), Renoux 2010, Vinogradova 2019, and Mohammed 2015 systematic review363720222324
Transdermal gel or spray Postmenopausal women, vasomotor symptoms EstroGel 0.75 mg/day (1 pump) to 1.5 mg/day (2 pumps); Divigel 0.25, 1.0 mg/day sachet; Elestrin 0.52 mg/day (1 pump) to 1.04 mg/day (2 pumps); Evamist 1, 3 sprays daily Reassessed annually FDA-labeled regimens3637
Vaginal Postmenopausal women, moderate-to-severe vulvovaginal atrophy / dyspareunia Estrace Cream 2, 4 g intravaginally daily for 1, 2 weeks, then 1 g 1, 3 times weekly; Vagifem / Yuvafem 10 microgram tablet intravaginally daily for 2 weeks, then twice weekly; Imvexxy 4 or 10 microgram softgel insert daily for 2 weeks, then twice weekly; Estring inserted for 90 days Indefinite while clinically beneficial; minimal systemic exposure at recommended doses Cochrane review (Suckling 2006); TX-004HR pivotal program; Mitchell 2018 JAMA Internal Medicine RCT29303133
Intramuscular Postmenopausal hypoestrogenism or gender-affirming feminizing therapy Estradiol valerate (Delestrogen): 10, 20 mg IM every 1, 4 weeks in menopausal use; in feminizing therapy, often 2, 10 mg IM weekly or 5, 20 mg IM every 2 weeks per Endocrine Society and WPATH guidelines. Estradiol cypionate (Depo-Estradiol): 1, 5 mg IM every 3, 4 weeks in menopausal use; 2, 10 mg IM every 1, 2 weeks in feminizing therapy Indefinite while clinically beneficial; titrated to target serum estradiol FDA-labeled regimens; Endocrine Society 2017 (Hembree); WPATH SOC v8 (Coleman 2022)3839
Subcutaneous pellet (compounded) Postmenopausal women or gender-affirming feminizing therapy Typical 12.5, 50 mg estradiol pellet implanted every 3, 6 months, often individualized; published PK and safety evidence is limited and largely observational Per implant interval; replaced when serum estradiol drops below the prescriber-defined target Observational pellet-clinic series; no FDA-approved estradiol pellet exists in the US4340
Compounded transdermal cream or troche Postmenopausal women or gender-affirming feminizing therapy, patient-specific Custom strengths per clinician prescription; target physiologic serum estradiol Reassessed at the same interval as for manufactured products Patient-specific 503A compounding under documented clinical reason4443

Doses listed reflect FDA-labeled regimens and published clinical-trial protocols, not RonanRx prescribing recommendations. The prescribing clinician selects formulation, route, and starting dose based on the patient's clinical context (indication, time since menopause, uterine status, VTE and breast cancer risk, formulation preference, and shared decision-making) 36.

Practical considerations across routes: oral estradiol carries higher VTE and stroke risk than transdermal in observational data 20, 23, 24, 22 and is generally avoided in women with elevated thrombotic risk 36. Transdermal patches and gels are first-line for women with metabolic syndrome, obesity, smoking, migraine with aura, hypertriglyceridemia, or prior VTE. Vaginal estradiol at recommended low doses produces minimal systemic exposure and is acceptable across most contraindications to systemic therapy 34, 35. IM and pellet routes are most common in gender-affirming feminizing therapy or in patients who prefer infrequent administration.

In women with an intact uterus, progestogen co-therapy is required to prevent endometrial hyperplasia and adenocarcinoma. Micronized progesterone is the bioidentical option; the E3N cohort 25 reported lower breast cancer risk with estradiol plus micronized progesterone or dydrogesterone than with estradiol plus synthetic progestins. Target the lowest effective dose for the shortest duration consistent with treatment goals, with annual reassessment per NAMS 2022 37 36.

Doses listed are literature context, not patient instructions. Dosing decisions are made by the prescribing doctor and tailored to the individual patient.

Safety

Estradiol Safety

Safety overview

Estradiol safety has been characterized in some of the largest randomized hormone-therapy programs ever conducted, supplemented by extensive observational pharmacoepidemiology. The most clinically important adverse events on systemic estradiol-based therapy are venous thromboembolism, ischemic stroke, gallbladder disease, and, when combined with a progestogen, breast cancer (regimen-, progestogen-, and duration-dependent) 37. Endometrial hyperplasia and adenocarcinoma are prevented by progestogen co-therapy in women with an intact uterus.

WHI 1 reported, on CEE + medroxyprogesterone in women aged 50, 79 (mean age 63) initiating therapy a decade past menopause, an excess of invasive breast cancer, coronary heart disease, stroke, and VTE that crossed a pre-specified global safety index 37. The CEE-alone arm in hysterectomized women 2, 7 showed a different risk profile, with reduced breast cancer incidence and a more favorable overall summary in younger women. The 18-year cumulative WHI follow-up 3 did not show excess all-cause mortality in either arm. Subsequent randomized programs in younger, recently menopausal women, KEEPS 18 and ELITE 17, have shaped current guidance that the risk profile depends heavily on time since menopause, age at initiation, and route.

Route-specific safety: transdermal and vaginal estradiol carry lower VTE and stroke risk than oral, based on consistent observational evidence from ESTHER 20, Renoux 2010 22, QResearch/CPRD 23, and a JCEM systematic review 24 37. Vaginal low-dose preparations produce minimal systemic exposure and are associated with favorable long-term safety in observational cohorts 34, 35.

Breast cancer: regimen, progestogen, and duration matter 37. E3N 25 reported lower breast cancer risk with estradiol plus micronized progesterone or dydrogesterone than with estradiol plus synthetic progestins. The Million Women Study 26 reported elevated risk across combined regimens. The WHI long-term follow-up 8 refined cumulative incidence. Other considerations include gallbladder disease (more common with oral estrogen), exacerbation of migraine with aura, and the absolute contraindications detailed in the next section.

Contraindications

Estradiol is contraindicated in: known, suspected, or history of breast cancer (and other estrogen-sensitive neoplasia); active or recent (within 1 year) arterial thromboembolic disease such as stroke or myocardial infarction; active or history of venous thromboembolism (DVT or pulmonary embolism) unless on therapeutic anticoagulation with carefully weighed risk/benefit and preference for a transdermal route; known thrombophilia (factor V Leiden, antiphospholipid antibody syndrome, protein C/S deficiency) without anticoagulation; known hepatic dysfunction or disease; known hypersensitivity to estradiol or any product excipient; pregnancy (category X, teratogenic; in particular, masculinization concerns for a female fetus); and undiagnosed abnormal genital bleeding 2023.

Relative contraindications and cautions per the Endocrine Society 2015 guideline 36 and NAMS 2022 37 include uncontrolled hypertension, hypertriglyceridemia (oral estradiol can elevate triglycerides further), migraine with aura (especially for oral estradiol given stroke risk), gallbladder disease, hereditary angioedema, severe hypertriglyceridemia, and an intact uterus without progestogen co-therapy (endometrial cancer risk) 20. Transdermal and vaginal routes are preferred over oral in patients with several of these relative cautions.

Drug interactions

Estradiol is metabolized hepatically by CYP1A2 and CYP3A4, with conjugation by UGT and SULT. Strong CYP3A4 inducers (rifampin, rifabutin, carbamazepine, phenytoin, phenobarbital, St. John's wort) reduce serum estradiol and may compromise efficacy. Strong CYP3A4 inhibitors (clarithromycin, itraconazole, ketoconazole, ritonavir-boosted regimens, grapefruit juice in high intake) raise estradiol exposure. Oral estradiol induces hepatic SHBG and binding globulins, which can affect interpretation of thyroid function tests (raises TBG and total T4 / total T3 while free hormone usually remains stable) and adrenal cortisol-binding globulin 37.

Estradiol can attenuate the response to lamotrigine (estrogen induces lamotrigine glucuronidation); cyclic oral estrogen regimens can produce cyclical breakthrough seizures in women on lamotrigine monotherapy. Concomitant tamoxifen, raloxifene, or aromatase inhibitors are not generally co-administered with estradiol given mechanistic opposition. Transdermal estradiol largely bypasses first-pass hepatic effects on thyroid and adrenal binding globulins, making it preferable in patients on complex thyroid replacement or with adrenal disease 36.

Adverse events

Common adverse events on systemic estradiol include breast tenderness, breakthrough bleeding (more frequent in the first months of combined therapy), nausea (oral), headache, mood changes, fluid retention, and application-site reactions (transdermal patch, adhesive irritation; gel, local erythema) 1. Vaginal estradiol commonly causes vaginal discharge or local irritation in the first weeks of therapy.

Serious adverse events with systemic estradiol-based hormone therapy, per WHI and observational pharmacoepidemiology: venous thromboembolism (DVT, pulmonary embolism, higher with oral than transdermal per ESTHER 20, Renoux 2010 22, QResearch/CPRD 23, and Mohammed 2015 24); ischemic stroke (also route-dependent); gallbladder disease and cholecystectomy; breast cancer (with combined regimens, progestogen- and duration-dependent, E3N 25, Million Women 26, WHI long-term follow-up 8); endometrial hyperplasia and adenocarcinoma in women with an intact uterus not receiving adequate progestogen co-therapy; and probable dementia in women aged 65+ initiating CEE ± MPA per WHIMS 9 12.

Vaginal low-dose estradiol at recommended regimens does not show consistent excess of breast cancer, endometrial cancer, or cardiovascular events in long-term observational cohorts 34, 35, reflecting the minimal systemic exposure at low local doses 33 1.

Monitoring

Monitoring Estradiol Therapy

Baseline assessment per the Endocrine Society 2015 guideline 36 and NAMS 2022 37: history of breast or other estrogen-sensitive cancer; personal or family history of VTE; cardiovascular risk profile (blood pressure, lipids, smoking, diabetes, BMI); migraine history with attention to aura; uterine status (intact uterus mandates progestogen co-therapy); age-appropriate breast and pelvic exam, mammography per national screening guidance; baseline endometrial assessment by symptom and risk profile (TVUS or biopsy if abnormal bleeding); and shared decision-making about expected benefits and risks.

On-therapy monitoring: annual reassessment of indication and dose; ongoing breast cancer screening per national guidance; prompt evaluation of any post-menopausal bleeding on combined therapy (TVUS and/or endometrial biopsy as clinically indicated); review of cardiovascular and thrombotic risk profile annually; serum estradiol may be measured to confirm absorption and target range in transdermal, IM, and pellet regimens, particularly in gender-affirming feminizing therapy 38, 39.

For gender-affirming feminizing therapy, the Endocrine Society 2017 38 and WPATH SOC v8 39 frameworks recommend serum estradiol and total testosterone monitoring at 3-month intervals during the first year and at least annually thereafter, with targets of estradiol in the premenopausal female physiologic range and total testosterone in the female physiologic range.

Special populations

Estradiol in Special Populations

Pregnancy

Estradiol is pregnancy category X, contraindicated in pregnancy. Exposure during pregnancy can cause fetal harm. Estradiol has no role in pregnancy maintenance; women of reproductive age on estradiol therapy who become pregnant should discontinue immediately and consult their prescriber 36.

Lactation

Estradiol is excreted in breast milk and can reduce milk production. Estradiol is generally not used during lactation; if therapy is clinically necessary, the prescribing clinician and patient weigh the risks and benefits.

Pediatric

Pediatric and adolescent use is restricted to specialty endocrinology contexts (Turner syndrome, hypogonadotropic hypogonadism, gender-affirming feminizing care under specialty guidance). Not addressed in detail on this page.

Geriatric

Women aged 65+ initiating systemic estradiol-based therapy face a different risk/benefit profile than recently menopausal women. WHIMS 9, 10 reported excess probable dementia in this age stratum on CEE ± MPA. The 2022 NAMS Position Statement 37 recommends against initiating systemic hormone therapy primarily for chronic disease prevention or cognitive protection in women aged 65+. Vaginal low-dose estradiol remains an acceptable option for genitourinary syndrome of menopause in older women given minimal systemic exposure 34, 35.

Hepatic impairment

Estradiol is contraindicated in known hepatic dysfunction or active liver disease. Transdermal and vaginal routes are preferred over oral in mild hepatic dysfunction when therapy is clinically necessary, given oral estradiol's first-pass hepatic load 36.

Evidence quality

Estradiol Evidence Quality

Evidence for estradiol in menopausal symptom management is among the largest in clinical medicine. WHI 1, 2, 4, 3 is the foundational randomized program, with substudies addressing breast cancer 7, 8, bone 6, cognition 9, 10, 11, VTE 13, and inflammatory biomarkers 14. The Endocrine Society 2015 guideline 36 and the 2022 NAMS Position Statement 37 provide the consensus framing.

The 'timing hypothesis', that initiating estradiol near menopause produces a different risk/benefit profile than initiating a decade later, is supported by ELITE 17 (oral estradiol slowed carotid IMT progression when started within 6 years of menopause but not when started 10+ years out), by KEEPS 18 (no excess vascular harm in recently menopausal women over 4 years), and by KEEPS-Cog 19 (no cognitive harm and possible mood benefit in recently menopausal women, in contrast to WHIMS in women aged 65+). EPAT 16 was an early supporting RCT. Salpeter 2006 27 and Salpeter 2009 28 meta-analyses had earlier suggested reduced CHD events and lower all-cause mortality in younger initiators.

Route-specific safety is supported by consistent observational pharmacoepidemiology, ESTHER 20, 21, Renoux 2010 22, QResearch/CPRD 23, and by the Mohammed 2015 JCEM systematic review and meta-analysis 24. Transdermal and vaginal routes carry lower VTE and stroke risk than oral.

Vaginal estradiol evidence: Cochrane review 29 established cross-formulation efficacy. The TX-004HR (Imvexxy) clinical program 30, 31 supported the low-dose vaginal softgel. Mitchell 2018 33 compared vaginal estradiol tablets, moisturizer, and placebo. Long-term observational safety in NHS 34 and WHI 35 cohorts does not show consistent excess of breast cancer, endometrial cancer, or cardiovascular events at recommended low doses.

For gender-affirming feminizing therapy, the Endocrine Society 2017 38 and WPATH SOC v8 39 frameworks define current best practice. For compounded bioidentical hormone therapy specifically, the 2020 NASEM consensus report 43 and Files 2011 40 are the principal critical reviews; they find insufficient evidence to support broad superiority claims and recommend restricting compounding to documented patient-specific clinical needs.

Compounded estradiol pellets have a limited published evidence base, pharmacokinetic and outcome data are largely observational from specialty pellet-therapy clinics. There is no FDA-approved estradiol pellet product in the United States.

Major studies

Major Estradiol Clinical Studies

StudyDesignParticipantsDurationFinding
WHI Combined CEE + MPA Principal Results (Rossouw 2002 JAMA) Randomized double-blind placebo-controlled trial of conjugated equine estrogens plus medroxyprogesterone acetate in postmenopausal women aged 50, 79 16608 Mean 5.2 years (stopped early) Trial stopped early for excess invasive breast cancer, coronary heart disease, stroke, and VTE that crossed a pre-specified global safety index; bone fractures reduced 1
WHI CEE-Alone (Hysterectomy) Results (Anderson 2004 JAMA) Randomized double-blind placebo-controlled trial of conjugated equine estrogens alone in postmenopausal women with prior hysterectomy 10739 Mean 6.8 years No excess CHD; increased stroke and VTE; reduced hip fractures; trend toward reduced breast cancer that reached significance in subsequent follow-up 2
WHI 18-Year Cumulative Follow-Up Mortality (Manson 2017 JAMA) Extended observational follow-up of both WHI hormone therapy trials 27347 Cumulative 18 years No statistically significant excess of all-cause mortality or cause-specific mortality (cardiovascular, cancer) in either WHI hormone-therapy arm vs placebo over 18-year cumulative follow-up 3
WHI Health Outcomes Intervention and Extended Phases (Manson 2013 JAMA) Pooled analysis of both WHI hormone-therapy trials across intervention and post-intervention follow-up — Cumulative through 13 years post-randomization Risk/benefit profile differed by age, time since menopause, and regimen; combined therapy carried more harm than estrogen-alone in older women; estrogen-alone had favorable profile in younger hysterectomized women 4
ELITE, Early versus Late Postmenopausal Estradiol (Hodis 2016 NEJM) Randomized double-blind placebo-controlled trial of oral estradiol stratified by years since menopause (<6 years vs ≥10 years) 643 Median 5 years Oral estradiol slowed progression of carotid intima-media thickness in women within 6 years of menopause but not in women 10+ years past menopause, strongest randomized support of the 'timing hypothesis' 17
KEEPS, Kronos Early Estrogen Prevention Study Overview (Miller 2019 Menopause) Synthesis of the 4-year randomized trial of oral CEE, transdermal estradiol, or placebo in recently menopausal women — 4 years No significant effect on carotid IMT or coronary artery calcification surrogates over 4 years; symptom benefit and bone effects favored active therapy; no excess vascular harm in this recently menopausal population 18
KEEPS-Cog (Gleason 2015 PLoS Medicine) Randomized double-blind placebo-controlled cognition substudy of KEEPS — 4 years No cognitive harm with oral CEE or transdermal estradiol initiated near menopause; possible mood benefit; in contrast to WHIMS findings in older women 19
WHIMS Dementia and Cognition (Shumaker 2004 / Espeland 2004 JAMA; Rapp 2003 JAMA) Randomized cognitive substudies of WHI in women aged 65+ — Mean 4, 5 years Excess probable dementia and decline in global cognitive function on CEE ± MPA in women aged 65+, basis for current guidance against initiating systemic hormone therapy primarily for cognitive protection in older women 91011
WHIMS-Y Younger Women Memory Study (Vaughan 2013 Brain Research) Long-term cognitive follow-up in women randomized to WHI hormone therapy at younger ages — — Baseline characterization for cognitive follow-up of younger WHI participants 12
EPAT, Estrogen in the Prevention of Atherosclerosis Trial (Hodis 2001 Ann Intern Med) Randomized double-blind placebo-controlled trial of oral micronized estradiol in postmenopausal women without prior CHD — 2 years Oral estradiol slowed progression of carotid intima-media thickness, early randomized support for vascular benefit in primary-prevention setting 16
WHI VTE Substudy (Cushman 2004 JAMA) Substudy of the WHI combined CEE + MPA trial — Mean 5.6 years Combined hormone therapy approximately doubled VTE risk vs placebo, with greater absolute risk in older and obese participants 13
WHI Fracture and Bone Density (Cauley 2003 JAMA) Substudy of the WHI combined CEE + MPA trial — Mean 5.6 years Combined hormone therapy reduced hip fractures, clinical vertebral fractures, and total fractures; increased BMD 6
WHI CEE-Alone Breast Cancer and Mammography (Stefanick 2006 JAMA) Substudy of the WHI estrogen-alone trial in hysterectomized women — Mean 7.1 years CEE alone did not increase invasive breast cancer (trend toward reduction); increased need for short-interval mammography follow-up 7
WHI Long-Term Breast Cancer Mortality (Chlebowski 2020 JAMA) Long-term follow-up of both WHI hormone-therapy trials for breast cancer outcomes — Cumulative 20+ years CEE alone reduced breast cancer incidence and mortality in hysterectomized women; CEE + MPA increased breast cancer incidence and mortality during and after intervention 8
PEPI, Postmenopausal Estrogen/Progestin Interventions (1996 JAMA) Randomized placebo-controlled trial of four estrogen-progestin regimens vs placebo in postmenopausal women — 3 years All active regimens preserved bone density; cyclic and continuous progestogen prevented endometrial hyperplasia in women with intact uterus while preserving bone benefit 15
Estrogen plus Progestin and Coronary Heart Disease (Manson 2003 NEJM) Pre-specified WHI substudy of coronary heart disease outcomes — Mean 5.2 years Increased CHD risk with combined CEE + MPA, with hazard concentrated in the first year of therapy 5
ESTHER, Hormone Therapy and VTE Route Differential (Canonico 2007 Circulation) Multicenter case-control study of postmenopausal women with VTE vs controls — Index VTE event vs matched controls Oral estrogen approximately quadrupled VTE risk; transdermal estrogen showed no significant excess vs no therapy; progestogen type also influenced risk (micronized progesterone and pregnane derivatives lower than norpregnane derivatives) 20
ESTHER ABO Blood Group Interaction (Canonico 2008 Thromb Haemost) ESTHER substudy on synergism between non-O blood group and oral estrogen — — Non-O blood group amplified VTE risk of oral but not transdermal estrogen in postmenopausal women 21
Renoux Population-Based HRT VTE Study (2010 J Thromb Haemost) Population-based nested case-control study in UK general practice — — Oral hormone replacement therapy increased VTE risk; transdermal therapy did not, replication of ESTHER in a separate population 22
Vinogradova HRT and VTE Nested Case-Control (2019 BMJ) Nested case-control studies in QResearch and CPRD UK primary-care databases 80396 — Oral hormone replacement therapy associated with increased VTE risk; transdermal preparations did not increase VTE risk, definitive observational evidence at scale for the route differential 23
Oral vs Transdermal Estrogen Vascular Events Meta-Analysis (Mohammed 2015 JCEM) Systematic review and meta-analysis — — Pooled randomized and observational evidence supports lower VTE and stroke risk with transdermal versus oral estrogen in postmenopausal women 24
E3N Cohort Breast Cancer by Progestogen (Fournier 2008 Breast Cancer Res Treat) Prospective French cohort of postmenopausal women in the E3N study 80377 — Estradiol plus micronized progesterone or dydrogesterone carried lower breast cancer risk than estradiol plus synthetic progestins, informs progestogen selection in combined estradiol regimens 25
Million Women Study Breast Cancer (Beral 2003 Lancet) Large UK cohort study of breast cancer incidence on hormone therapy 1084110 — Current use of combined hormone therapy substantially elevated breast cancer incidence and mortality; estrogen-only therapy showed a smaller increase 26
Salpeter Younger-Women CHD Meta-Analysis (Salpeter 2006 J Gen Intern Med) Meta-analysis of randomized trials of hormone therapy and CHD events by age and time since menopause — — Reduced CHD events in younger postmenopausal initiators; neutral or increased events in older initiators, quantitative support for the timing hypothesis 27
Salpeter Bayesian Mortality Meta-Analysis (Salpeter 2009 Am J Med) Bayesian meta-analysis of hormone therapy and mortality in younger postmenopausal women — — Hormone therapy associated with lower total mortality in younger postmenopausal women across pooled randomized data 28
Cochrane Local Vaginal Estrogen for Vaginal Atrophy (Suckling 2006) Cochrane systematic review of local vaginal estrogen preparations — — Vaginal estrogen, across cream, tablet, ring formulations, produced significant symptomatic improvement of vaginal atrophy with minimal systemic effects 29
Cochrane Long-Term Hormone Therapy (Marjoribanks 2017/2018) Updated Cochrane systematic review of long-term hormone therapy for perimenopausal and postmenopausal women — — Quantified absolute risks and benefits across cardiovascular, breast cancer, fracture, and dementia endpoints by age at initiation 42
Boardman Cochrane Hormone Therapy for CV Disease Prevention (2015) Cochrane systematic review of randomized hormone-therapy trials for cardiovascular disease prevention — — Hormone therapy is not recommended for primary or secondary prevention of cardiovascular disease; subgroup analysis supports age-dependent risk profile 41
TX-004HR / Imvexxy Vaginal Estradiol Softgel (Constantine 2017; Kingsberg 2017) Phase 3 randomized double-blind placebo-controlled trials of low-dose vaginal estradiol softgel insert in postmenopausal women with moderate-to-severe dyspareunia due to vulvar/vaginal atrophy — — TX-004HR (4 and 10 microgram) improved most-bothersome symptom of dyspareunia and vaginal physiology endpoints with minimal systemic absorption; basis for Imvexxy FDA approval (2018) 303132
Vaginal Estradiol vs Moisturizer vs Placebo (Mitchell 2018 JAMA Intern Med) Randomized double-blind placebo-controlled trial in postmenopausal women with bothersome vulvovaginal symptoms 302 12 weeks Both low-dose vaginal estradiol tablet and vaginal moisturizer improved symptoms similarly, with both modestly better than placebo; minimal systemic estradiol absorption 33
Vaginal Estrogen and Chronic Disease Risk in NHS (Bhupathiraju 2018 Menopause) Prospective observational analysis in the Nurses' Health Study — — Long-term vaginal estrogen use was not associated with elevated risk of cardiovascular events or invasive cancer overall 34
Vaginal Estrogen Safety in WHI Observational Cohort (Crandall 2018 Menopause) Observational follow-up of vaginal estrogen users in the WHI — — Vaginal estrogen use was not associated with increased breast cancer, endometrial cancer, or cardiovascular events compared with non-users in this cohort 35
Files Bioidentical Hormone Therapy Review (Files 2011 Mayo Clin Proc) Critical narrative review — — Reviewed bioidentical hormone marketing claims and clinical evidence; concluded that compounded bioidentical hormones are not safer or more effective than FDA-approved bioidentical preparations, and that broad marketing claims of superiority are not supported by evidence 40
NAMS 2022 Hormone Therapy Position Statement Consensus position statement — — Current consensus framework for menopausal hormone therapy: most favorable risk/benefit in symptomatic women within 10 years of menopause and under age 60; route-, regimen-, and duration-specific guidance; not recommended for primary chronic disease prevention 37
Endocrine Society 2015 Menopause Guideline (Stuenkel) Clinical practice guideline — — Diagnostic, therapeutic, and monitoring recommendations for menopausal hormone therapy across the indication range 36
Endocrine Society 2017 Gender-Dysphoric/Gender-Incongruent Guideline (Hembree) Clinical practice guideline — — Feminizing hormone therapy recommendations including estradiol dosing across routes (oral, transdermal, IM ester, sublingual), monitoring (serum estradiol and total testosterone targets), and shared decision-making framework 38
WPATH Standards of Care Version 8 (Coleman 2022) International multidisciplinary consensus guideline — — Defines current best-practice framework for estradiol use in feminizing gender-affirming care across the lifespan 39
NASEM 2020 Compounded Bioidentical Hormone Therapy Report Consensus report of the National Academies of Sciences, Engineering, and Medicine — — Found insufficient evidence to support broad claims of safety or efficacy advantages of compounded bioidentical hormones over FDA-approved manufactured products; recommended restricting compounded preparations to documented patient-specific clinical needs 43
Marjoribanks Cochrane Corner Long-Term Hormone Therapy (2018 Heart) Cochrane Corner narrative synthesis of the long-term hormone therapy review — — Quantified absolute risks for cardiovascular disease, VTE, breast cancer, and fracture across age strata; informed contemporary risk communication 42
WHI Estrogen Plus Progestin and Inflammatory Biomarkers (Pradhan 2002 JAMA) Prospective analysis within WHI — — Combined CEE + MPA elevated CRP and other inflammatory biomarkers, mechanistic context for the early-stage CHD signal 14

Mechanism detail

Detailed Mechanism of Estradiol

Estrogen receptor structure and isoforms. The classical estrogen receptors ERα (encoded by ESR1 on chromosome 6) and ERβ (encoded by ESR2 on chromosome 14) are nuclear hormone receptors with a modular domain organization shared across the superfamily, N-terminal activation function-1 (AF-1) domain, central DNA-binding domain with two zinc-finger motifs that recognize estrogen-response elements, hinge region, and C-terminal ligand-binding domain that houses AF-2 37. Unliganded receptors are complexed with heat-shock chaperones; ligand binding induces conformational change, dimerization, nuclear translocation, and recruitment of coactivator complexes that drive transcription of estrogen-responsive genes.

Genomic versus nongenomic signaling. The genomic pathway operates on a transcriptional timescale of hours and underlies most of estradiol's chronic effects on tissue growth, gene expression, and homeostasis. The nongenomic pathway operates on a seconds-to-minutes timescale through plasma-membrane-associated complexes: a fraction of ERα localizes to caveolae and signals through Gαi, src, MAPK, and PI3K/Akt; a separate G protein-coupled receptor GPER (GPR30) drives rapid kinase cascades and endothelial nitric oxide synthase activation. Nongenomic signaling is implicated in estradiol's acute vasodilatory effects and in some neuroprotective and metabolic actions 17.

Tissue selectivity. The same circulating estradiol produces tissue-specific effects depending on the local ERα/ERβ ratio, coregulator complement, and the presence of metabolizing enzymes. Uterus, mammary epithelium, and liver are ERα-dominant; vascular endothelium, lung, and parts of the CNS are ERβ-dominant 17. The selective estrogen receptor modulator (SERM) class, tamoxifen, raloxifene, bazedoxifene, exploits this tissue selectivity by acting as an agonist in some tissues (bone) and antagonist in others (breast).

First-pass hepatic effects and route-dependence. Oral estradiol is extensively metabolized to estrone (E1) and estrone sulfate (E1S) on first pass through the liver, producing a markedly different metabolite profile than endogenous ovarian secretion. The hepatic exposure that follows oral dosing also induces synthesis of sex hormone-binding globulin (SHBG), thyroid-binding globulin, corticosteroid-binding globulin, angiotensinogen, and several coagulation factors, driving the higher VTE and stroke risk seen with oral versus transdermal estradiol in observational studies 20, 23, 24 17. Transdermal, vaginal, and subcutaneous pellet routes largely bypass first-pass, producing serum estradiol exposure closer to the premenopausal physiologic profile and a more favorable hepatic-coagulation signature 22.

Metabolism. Estradiol is metabolized hepatically by CYP1A2, CYP3A4, and other isoforms to 2-hydroxyestradiol, 4-hydroxyestradiol, and 16α-hydroxyestrone, with subsequent methylation by COMT and conjugation by SULT and UGT 17. The catechol estrogens and their semiquinones have been studied as putative carcinogenic intermediates in breast tissue. Excretion is mostly urinary as glucuronide and sulfate conjugates.

Endometrial proliferation and progestogen co-therapy. Unopposed estradiol drives endometrial epithelial proliferation through ERα; in women with an intact uterus, this produces dose- and duration-dependent increases in endometrial hyperplasia (including atypia) and adenocarcinoma. Cyclic or continuous progestogen administration opposes this effect by downregulating endometrial estrogen receptors and inducing decidualization. The PEPI trial 15 established that all four common combined regimens (CEE alone in hysterectomized women, CEE + cyclic MPA, CEE + continuous MPA, CEE + cyclic micronized progesterone) preserved bone density relative to placebo while combined regimens prevented endometrial hyperplasia. Compounded bioidentical estradiol delivered with micronized progesterone is widely used in postmenopausal women with an intact uterus, with the E3N cohort 25 providing the largest observational signal that micronized progesterone or dydrogesterone produces lower breast cancer risk than synthetic progestins when paired with estradiol 3617.

Pharmacology

Estradiol Pharmacokinetics & Pharmacodynamics

Pharmacokinetics

Oral estradiol has low and variable bioavailability (around 5%) due to extensive first-pass intestinal and hepatic metabolism to estrone and estrone sulfate. The first-pass exposure drives induction of hepatic SHBG, binding globulins, angiotensinogen, and coagulation factors, the mechanistic basis for the higher VTE and stroke risk seen with oral versus non-oral routes 20, 23. Peak serum estradiol occurs 1, 2 hours after oral dosing.

Transdermal patches deliver estradiol continuously through skin; serum levels reach near-steady-state within 24, 48 hours of patch application and are maintained throughout the wear interval (3.5 or 7 days depending on product). Transdermal gels and sprays produce steady-state within several days of daily application. Transdermal routes bypass first-pass and produce serum estradiol exposure closer to the premenopausal physiologic profile, with markedly lower hepatic SHBG and coagulation-factor induction 24, 22.

Vaginal estradiol at low local doses (Vagifem 10 microgram tablet, Imvexxy 4 microgram softgel, Estring 7.5 microgram/day ring) produces minimal systemic exposure, serum estradiol typically remains in the postmenopausal physiologic range or modestly above, well below systemic-replacement levels 33. Higher-dose vaginal preparations (Estrace Cream at standard regimen, Femring at systemic dose) produce serum estradiol comparable to oral or transdermal systemic therapy.

Intramuscular estradiol esters (valerate, cypionate) produce peak serum estradiol several days after injection with gradual decline over 1, 4 weeks depending on ester and dose. Peak-trough variability is wider than with transdermal continuous delivery, which is relevant to symptom control and patient experience in both menopausal and gender-affirming use. Subcutaneous estradiol pellets release estradiol over 3, 6 months in observational PK series; the published PK literature is limited compared with testosterone pellets.

Pharmacodynamics

Pharmacodynamic effects are dose-dependent and route-dependent. Replacement to premenopausal physiologic serum estradiol relieves vasomotor symptoms, restores vaginal and urethral epithelial maturation, suppresses bone resorption and preserves bone density 15, 6, and produces favorable changes in lipid profile and endothelial function. Oral estradiol's hepatic exposure also induces SHBG, angiotensinogen, triglycerides, and coagulation factors, pharmacodynamic effects largely absent from transdermal and vaginal routes 20, 23.

Endometrial pharmacodynamics: unopposed estradiol drives endometrial proliferation in women with an intact uterus and increases endometrial cancer risk; cyclic or continuous progestogen co-therapy opposes this effect 15. Breast pharmacodynamics: estradiol stimulates breast epithelial proliferation; combined therapy with synthetic progestins amplifies breast cancer risk more than combined therapy with micronized progesterone or dydrogesterone 25. CNS pharmacodynamics: estradiol's effects on cognition and dementia depend on time of initiation, with neutral-to-favorable effects in recently menopausal women 19 and excess dementia in women aged 65+ on CEE ± MPA 9.

Comparative formulations

Comparing Estradiol Formulations

Choice of estradiol formulation balances patient preference, route-specific safety, indication (systemic vs local), and the manufactured-product range 44. Oral estradiol (Estrace) is convenient and inexpensive but carries the highest VTE and stroke risk among the routes 20, 23, 24. Transdermal patches (Climara weekly; Vivelle-Dot, Minivelle, Alora twice-weekly) provide steady serum levels and lower thrombotic risk than oral, with patch-adhesive sensitivity as the main practical limitation. Transdermal gels (Divigel, EstroGel, Elestrin) and sprays (Evamist) offer dosing flexibility and avoid patch adhesives but require attention to inter-personal transfer.

Vaginal preparations are preferred when the indication is limited to genitourinary syndrome of menopause: low-dose tablets (Vagifem, Yuvafem 10 microgram), softgel insert (Imvexxy 4 or 10 microgram), low-dose ring (Estring), and cream (Estrace Cream) all produce minimal systemic exposure at recommended low-dose regimens 33, 34 44. Higher-dose systemic vaginal rings (Femring) treat both systemic and local symptoms.

Intramuscular ester depots (Delestrogen, Depo-Estradiol) are most commonly used in feminizing gender-affirming therapy and selected menopausal contexts where infrequent dosing is preferred. Compounded preparations expand the route palette: custom transdermal cream strengths between manufactured gel doses; allergen-free formulations for patch-adhesive-reactive patients; pellets (no FDA-approved estradiol pellet exists in the US); troches; and gender-affirming-specific strengths and vehicles 44. RonanRx compounds these preparations on patient-specific prescription, with documented clinical reason for compounding. The pharmacist review confirms the prescribed formulation is responsive to a documented patient-specific need and is not routine substitution for a manufactured product.

Storage

Estradiol Storage and Handling

Compounded estradiol preparations are stored per the dispensing label. Sterile injectable preparations in oil (compounded estradiol valerate or cypionate) are stored at controlled room temperature (USP definition 20, 25°C, with allowed excursions 15, 30°C) protected from light; refrigeration may cause crystallization of higher-concentration ester-in-oil solutions. Beyond-use dating follows USP <797> for sterile compounded preparations 46.

Non-sterile compounded forms, transdermal creams, troches, oral capsules, vaginal creams, are stored per the dispensing label at controlled room temperature with light-resistant packaging, with beyond-use dating per USP <795> non-sterile compounding standards 45. Estradiol pellets are stored per the supplier's storage instructions until implantation.

RonanRx operations

Estradiol Compounding & Operations

503A compounding

RonanRx compounds estradiol preparations under 503A on patient-specific prescriptions. Sterile injectable preparations (compounded estradiol valerate or cypionate in oil) follow USP General Chapter <797> for sterile pharmaceutical compounding, with documented active-ingredient sourcing (USP/NF grade), sterility and endotoxin testing per applicable risk-level requirements, gravimetric/volumetric verification, and full lot traceability 4546. Non-sterile preparations (troches, transdermal creams, oral capsules, vaginal creams, suppositories) follow USP General Chapter <795>. Estradiol pellets are implanted only on documented patient-specific prescription with clinician-defined dose.

Estradiol is not a controlled substance, but its dispensing follows standard prescription-only handling, prescriber verification, and patient identification protocols. RonanRx does not dispense compounded estradiol on a direct-to-consumer basis 44.

Pharmacist review

Each prescription for compounded estradiol undergoes pharmacist review prior to dispensing. The review confirms: a documented patient-specific clinical reason for the compounded preparation (formulation/route not in the manufactured market, custom strength, allergen sensitivity, or gender-affirming-care dose outside menopausal labeling); diagnostic basis consistent with the Endocrine Society 2015 36, NAMS 2022 37, or Endocrine Society 2017 transgender guideline 38 / WPATH SOC v8 39 framework as applicable; absence of contraindications (history of breast or other estrogen-sensitive cancer, active VTE or recent arterial event without anticoagulation, hepatic dysfunction, pregnancy, undiagnosed abnormal bleeding); confirmation of baseline monitoring (uterine status with progestogen co-therapy as indicated, breast and CV risk profile); and appropriate prescription elements.

RonanRx does not fill prescriptions for compounded estradiol that read as routine substitution for an available manufactured product without documented clinical rationale, consistent with FDA guidance on compounded copies of approved drugs 44 and the NASEM 2020 framework on compounded bioidentical hormone therapy 43.

Quality and traceability

Estradiol API is sourced from FDA-registered facilities with documented certificates of analysis. Each batch is recorded with lot numbers traceable to API source, compounding date, beyond-use date, and dispensing pharmacist of record. Sterile preparations carry sterility and endotoxin test documentation per USP <797> risk-level requirements 46. Non-sterile preparations carry compounding-record documentation per USP <795> 45.

Cold chain

Most compounded estradiol preparations are not cold-chain products. Injectable ester-in-oil preparations, transdermal creams, troches, capsules, and vaginal creams are shipped at controlled room temperature. Patients are instructed to store at room temperature in tightly closed light-resistant containers and to contact the pharmacy if shipping temperature integrity is in doubt.

FAQ

Frequently Asked Questions About Estradiol

Is compounded estradiol the same molecule as Estrace or Climara?

Yes, the active ingredient (17β-estradiol) is the same bioidentical molecule. The difference is the manufacturing pathway and the FDA approval status. Estrace, Climara, Vivelle-Dot, Vagifem, Imvexxy, Estring, Femring, Delestrogen, Depo-Estradiol, and other branded estradiol products are FDA-approved manufactured products. Compounded preparations are pharmacy-prepared on a patient-specific prescription and are not FDA-approved. The 2020 NASEM consensus report (nasem2020) found insufficient evidence to support broad claims that compounded bioidentical hormones are safer or more effective than FDA-approved bioidentical preparations 434440.

When does compounded estradiol make clinical sense?

Common documented reasons include: a route or strength the manufactured market does not provide (estradiol pellet, there is no FDA-approved estradiol pellet in the US; custom transdermal cream strength between commercial gel doses; ultra-low or above-label vaginal strength for selected refractory atrophy); allergen sensitivity to a manufactured product's adhesive or vehicle; or a gender-affirming-care dose outside the labeled ranges of approved menopausal products per the Endocrine Society 2017 and WPATH SOC v8 frameworks 4438. Routine substitution of compounded for manufactured product without a documented reason is not appropriate 39.

Is transdermal estradiol really safer than oral?

For venous thromboembolism (DVT, pulmonary embolism) and stroke, the consistent observational evidence, ESTHER (Canonico 2007), Renoux 2010, and the large QResearch/CPRD nested case-control (Vinogradova 2019), summarized in the Mohammed 2015 JCEM systematic review, shows lower risk with transdermal than oral estradiol 202324. The mechanism is straightforward: oral estradiol passes through the liver first and induces coagulation factors and SHBG; transdermal estradiol largely bypasses first-pass. For symptom relief and bone benefit, both routes are effective 22.

What did the WHI actually show, and does it still apply?

WHI (Rossouw 2002) randomized older postmenopausal women (mean age 63, average a decade past menopause) to conjugated equine estrogens plus medroxyprogesterone or placebo, and reported an excess of breast cancer, CHD, stroke, and VTE that stopped the trial early 127. The estrogen-alone arm in hysterectomized women (Anderson 2004; Stefanick 2006) showed a different profile, with reduced breast cancer. The 18-year follow-up (Manson 2017) showed no excess all-cause mortality in either arm. Subsequent randomized programs in recently menopausal women, ELITE (Hodis 2016) and KEEPS (Miller 2019), have shaped current guidance that age and time since menopause matter substantially, and that transdermal routes and bioidentical progesterone may further refine the risk profile 31718.

What about breast cancer risk?

Risk depends on regimen, progestogen, duration, and baseline risk. The combined estrogen-plus-progestogen regimens elevate breast cancer risk in WHI and the Million Women Study, with synthetic progestins carrying higher risk than micronized progesterone or dydrogesterone per the E3N cohort (Fournier 2008) 2526. The estrogen-alone arm in WHI in hysterectomized women showed reduced breast cancer incidence 12. Vaginal low-dose estradiol does not show consistent breast cancer signal in long-term observational cohorts (Bhupathiraju 2018; Crandall 2018) 3435.

Are estradiol pellets FDA-approved?

No. There is no FDA-approved estradiol pellet product in the United States, the only marketed pellet (Testopel) is testosterone. Any estradiol pellet preparation in US practice is inherently compounded under 503A on a patient-specific prescription 44. The published evidence base for estradiol pellets is more limited than for transdermal patches, gels, or vaginal preparations; the prescribing clinician and patient discuss the trade-offs 43.

Is compounded bioidentical hormone therapy safer or more 'natural' than FDA-approved products?

The 2020 National Academies consensus report (nasem2020) found insufficient evidence to support broad claims of safety, efficacy, or 'naturalness' advantages of compounded bioidentical hormone therapy over FDA-approved bioidentical preparations 434037. The Files 2011 Mayo Clinic Proceedings review made the same point. The molecule (17β-estradiol) is identical between compounded and FDA-approved bioidentical products. The case for compounding is patient-specific clinical need, a formulation, route, strength, or vehicle the manufactured market does not provide, not broad marketing superiority.

What about estradiol for gender-affirming feminizing therapy?

Estradiol is the principal hormone of feminizing therapy. The Endocrine Society 2017 guideline (Hembree) and WPATH Standards of Care Version 8 (Coleman 2022) define current best practice for dosing across oral, sublingual, transdermal patch and gel, intramuscular valerate or cypionate, and compounded pellet routes; monitoring (serum estradiol and total testosterone with co-administered anti-androgen as appropriate); and shared decision-making 3839. RonanRx compounded estradiol in this context is dispensed only on a patient-specific prescription from the patient's clinician.

Does RonanRx sell estradiol directly to patients?

No. Estradiol is a prescription-only product dispensed on a patient-specific prescription written by a licensed prescriber for an identified patient, with pharmacist review before dispensing. RonanRx is not a direct-to-consumer storefront 44.

Clinician resource

Download the Estradiol Clinical Monograph (PDF)

The full white paper covers every section on this page plus chemical identity, evidence grading, indication-by-indication summaries, research gaps, and reference appendix. Suitable for sharing with prescribing doctors and pharmacist reviewers.

Download information packet ↓

References

References

  1. [rossouw2002whi] Writing Group for the Women's Health Initiative Investigators; Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002. PMID 12117397. (accessed 2026-05-11)
  2. [anderson2004whi] Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson J, Margolis K, Ockene J, O'Sullivan MJ, Phillips L, Prentice RL, Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefanick ML, Van Horn L, Wactawski-Wende J, Wallace R, Wassertheil-Smoller S. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004. PMID 15082697. (accessed 2026-05-11)
  3. [manson2017whi] Manson JE, Aragaki AK, Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Chlebowski RT, Howard BV, Thomson CA, Margolis KL, Lewis CE, Stefanick ML, Jackson RD, Johnson KC, Martin LW, Shumaker SA, Espeland MA, Wactawski-Wende J; WHI Investigators. Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women's Health Initiative Randomized Trials. JAMA. 2017. PMID 28898378. (accessed 2026-05-11)
  4. [manson2013whi] Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL, Anderson G, Howard BV, Thomson CA, LaCroix AZ, Wactawski-Wende J, Jackson RD, Limacher M, Margolis KL, Wassertheil-Smoller S, Beresford SA, Cauley JA, Eaton CB, Gass M, Hsia J, Johnson KC, Kooperberg C, Kuller LH, Lewis CE, Liu S, Martin LW, Ockene JK, O'Sullivan MJ, Powell LH, Simon MS, Van Horn L, Vitolins MZ, Wallace RB. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA. 2013. PMID 24084921. (accessed 2026-05-11)
  5. [manson2003chd] Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Trevisan M, Black HR, Heckbert SR, Detrano R, Strickland OL, Wong ND, Crouse JR, Stein E, Cushman M; Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. New England Journal of Medicine. 2003. PMID 12904517. (accessed 2026-05-11)
  6. [cauley2003whi] Cauley JA, Robbins J, Chen Z, Cummings SR, Jackson RD, LaCroix AZ, LeBoff M, Lewis CE, McGowan J, Neuner J, Pettinger M, Stefanick ML, Wactawski-Wende J, Watts NB; Women's Health Initiative Investigators. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA. 2003. PMID 14519707. (accessed 2026-05-11)
  7. [stefanick2006whi] Stefanick ML, Anderson GL, Margolis KL, Hendrix SL, Rodabough RJ, Paskett ED, Lane DS, Hubbell FA, Assaf AR, Sarto GE, Schenken RS, Yasmeen S, Lessin L, Chlebowski RT; WHI Investigators. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA. 2006. PMID 16609086. (accessed 2026-05-11)
  8. [chlebowski2020whilongterm] Chlebowski RT, Anderson GL, Aragaki AK, Manson JE, Stefanick ML, Pan K, Barrington W, Kuller LH, Simon MS, Lane D, Johnson KC, Rohan TE, Gass MLS, Cauley JA, Paskett ED, Sattari M, Prentice RL. Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women's Health Initiative Randomized Clinical Trials. JAMA. 2020. PMID 32721007. (accessed 2026-05-11)
  9. [shumaker2004whims] Shumaker SA, Legault C, Kuller L, Rapp SR, Thal L, Lane DS, Fillit H, Stefanick ML, Hendrix SL, Lewis CE, Masaki K, Coker LH; Women's Health Initiative Memory Study. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA. 2004. PMID 15213206. (accessed 2026-05-11)
  10. [espeland2004whims] Espeland MA, Rapp SR, Shumaker SA, Brunner R, Manson JE, Sherwin BB, Hsia J, Margolis KL, Hogan PE, Wallace R, Dailey M, Freeman R, Hays J; Women's Health Initiative Memory Study. Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. JAMA. 2004. PMID 15213207. (accessed 2026-05-11)
  11. [rapp2003whims] Rapp SR, Espeland MA, Shumaker SA, Henderson VW, Brunner RL, Manson JE, Gass ML, Stefanick ML, Lane DS, Hays J, Johnson KC, Coker LH, Dailey M, Bowen D; WHIMS Investigators. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003. PMID 12771113. (accessed 2026-05-11)
  12. [vaughan2013whimsy] Vaughan L, Espeland MA, Snively B, Shumaker SA, Rapp SR, Shupe J, Hendrix S, Tindle H, Sarto G, Resnick SM. The rationale, design, and baseline characteristics of the Women's Health Initiative Memory Study of Younger Women (WHIMS-Y). Brain Research. 2013. PMID 23578696. (accessed 2026-05-11)
  13. [cushman2004whivte] Cushman M, Kuller LH, Prentice R, Rodabough RJ, Psaty BM, Stafford RS, Sidney S, Rosendaal FR; Women's Health Initiative Investigators. Estrogen plus progestin and risk of venous thrombosis. JAMA. 2004. PMID 15467059. (accessed 2026-05-11)
  14. [pradhan2002whi] Pradhan AD, Manson JE, Rossouw JE, Siscovick DS, Mouton CP, Rifai N, Wallace RB, Jackson RD, Pettinger MB, Ridker PM. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study. JAMA. 2002. PMID 12190368. (accessed 2026-05-11)
  15. [pepi1996bone] The Writing Group for the PEPI Trial. Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. The Writing Group for the PEPI.. JAMA. 1996. PMID 8892713. (accessed 2026-05-11)
  16. [hodis2001epat] Hodis HN, Mack WJ, Lobo RA, Shoupe D, Sevanian A, Mahrer PR, Selzer RH, Liu Cr CR, Liu Ch CH, Azen SP; Estrogen in the Prevention of Atherosclerosis Trial Research Group. Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Annals of Internal Medicine. 2001. PMID 11730394. (accessed 2026-05-11)
  17. [hodis2016elite] Hodis HN, Mack WJ, Henderson VW, Shoupe D, Budoff MJ, Hwang-Levine J, Li Y, Feng M, Dustin L, Kono N, Stanczyk FZ, Selzer RH, Azen SP; ELITE Research Group. Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol. New England Journal of Medicine. 2016. PMID 27028912. (accessed 2026-05-11)
  18. [miller2019keeps] Miller VM, Naftolin F, Asthana S, Black DM, Brinton EA, Budoff MJ, Cedars MI, Dowling NM, Gleason CE, Hodis HN, Jayachandran M, Kantarci K, Lobo RA, Manson JE, Pal L, Santoro NF, Taylor HS, Harman SM. The Kronos Early Estrogen Prevention Study (KEEPS): what have we learned?. Menopause. 2019. PMID 31453973. (accessed 2026-05-11)
  19. [gleason2015keepscog] Gleason CE, Dowling NM, Wharton W, Manson JE, Miller VM, Atwood CS, Brinton EA, Cedars MI, Lobo RA, Merriam GR, Neal-Perry G, Santoro NF, Taylor HS, Black DM, Budoff MJ, Hodis HN, Naftolin F, Harman SM, Asthana S. Effects of Hormone Therapy on Cognition and Mood in Recently Postmenopausal Women: Findings from the Randomized, Controlled KEEPS-Cognitive and Affective Study. PLoS Medicine. 2015. PMID 26035291. (accessed 2026-05-11)
  20. [canonico2007esther] Canonico M, Oger E, Plu-Bureau G, Conard J, Meyer G, Lévesque H, Trillot N, Barrellier MT, Wahl D, Emmerich J, Scarabin PY; Estrogen and Thromboembolism Risk (ESTHER) Study Group. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation. 2007. PMID 17309934. (accessed 2026-05-11)
  21. [canonico2008esther] Canonico M, Olié V, Carcaillon L, Trillot N, Oger E, Lévesque H, Plu-Bureau G, Conard J, Meyer G, Scarabin PY. Synergism between non-O blood group and oral estrogen in the risk of venous thromboembolism among postmenopausal women: the ESTHER study. Thrombosis and Haemostasis. 2008. PMID 18217166. (accessed 2026-05-11)
  22. [renoux2010transdermal] Renoux C, Dell'Aniello S, Suissa S. Hormone replacement therapy and the risk of venous thromboembolism: a population-based study. Journal of Thrombosis and Haemostasis. 2010. PMID 20230416. (accessed 2026-05-11)
  23. [vinogradova2019bmj] Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ. 2019. PMID 30626577. (accessed 2026-05-11)
  24. [mohammed2015orvtrans] Mohammed K, Abu Dabrh AM, Benkhadra K, Al Nofal A, Carranza Leon BG, Prokop LJ, Montori VM, Faubion SS, Murad MH. Oral vs Transdermal Estrogen Therapy and Vascular Events: A Systematic Review and Meta-Analysis. Journal of Clinical Endocrinology & Metabolism. 2015. PMID 26544651. (accessed 2026-05-11)
  25. [fournier2008e3n] Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Research and Treatment. 2008. PMID 17333341. (accessed 2026-05-11)
  26. [beral2003mws] Million Women Study Collaborators; Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003. PMID 12927427. (accessed 2026-05-11)
  27. [salpeter2006chd] Salpeter SR, Walsh JM, Greyber E, Salpeter EE. Brief report: Coronary heart disease events associated with hormone therapy in younger and older women. A meta-analysis. Journal of General Internal Medicine. 2006. PMID 16686814. (accessed 2026-05-11)
  28. [salpeter2009mortality] Salpeter SR, Cheng J, Thabane L, Buckley NS, Salpeter EE. Bayesian meta-analysis of hormone therapy and mortality in younger postmenopausal women. American Journal of Medicine. 2009. PMID 19854329. (accessed 2026-05-11)
  29. [suckling2006cochrane] Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database of Systematic Reviews. 2006. PMID 17054136. (accessed 2026-05-11)
  30. [constantine2017imvexxy] Constantine GD, Simon JA, Pickar JH, Archer DF, Kushner H, Bernick B, Mirkin S. Consistency of Effect with a Low-Dose, Estradiol Vaginal Capsule (TX-004HR): Evaluating Improvement in Vaginal Physiology and Moderate-to-Severe Dyspareunia in Subgroups of Postmenopausal Women. Journal of Women's Health. 2017. PMID 28355090. (accessed 2026-05-11)
  31. [kingsberg2017tx004hr] Kingsberg SA, Derogatis L, Simon JA, Constantine GD, Bernick B, Mirkin S. Patient acceptability and satisfaction with a low-dose solubilized vaginal estradiol softgel capsule, TX-004HR. Menopause. 2017. PMID 28195995. (accessed 2026-05-11)
  32. [imvexxy2018paton] Paton DM. Estradiol vaginal inserts (Imvexxy): effective in genitourinary syndrome of menopause without increasing systemic estrogen levels.. Drugs of Today (Barcelona). 2018. PMID 30539166. (accessed 2026-05-11)
  33. [mitchell2018vagest] Mitchell CM, Reed SD, Diem S, Larson JC, Newton KM, Ensrud KE, LaCroix AZ, Caan B, Guthrie KA. Efficacy of Vaginal Estradiol or Vaginal Moisturizer vs Placebo for Treating Postmenopausal Vulvovaginal Symptoms: A Randomized Clinical Trial. JAMA Internal Medicine. 2018. PMID 29554173. (accessed 2026-05-11)
  34. [bhupathiraju2018vagne] Bhupathiraju SN, Grodstein F, Stampfer MJ, Willett WC, Crandall CJ, Shifren JL, Manson JE. Vaginal estrogen use and chronic disease risk in the Nurses' Health Study. Menopause. 2018. PMID 30562320. (accessed 2026-05-11)
  35. [crandall2018vagest] Crandall CJ, Hovey KM, Andrews CA, Chlebowski RT, Stefanick ML, Lane DS, Shifren J, Chen C, Kaunitz AM, Cauley JA, Manson JE. Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women's Health Initiative Observational Study. Menopause. 2018. PMID 28816933. (accessed 2026-05-11)
  36. [stuenkel2015endo] Stuenkel CA, Davis SR, Gompel A, Lumsden MA, Murad MH, Pinkerton JV, Santen RJ. Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism. 2015. PMID 26444994. (accessed 2026-05-11)
  37. [nams2022] The 2022 Hormone Therapy Position Statement of The North American Menopause Society Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022. PMID 35797481. (accessed 2026-05-11)
  38. [hembree2017transgender] Hembree WC, Cohen-Kettenis PT, Gooren L, Hannema SE, Meyer WJ, Murad MH, Rosenthal SM, Safer JD, Tangpricha V, T'Sjoen GG. Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism. 2017. PMID 28945902. (accessed 2026-05-11)
  39. [coleman2022wpath] Coleman E, Radix AE, Bouman WP, Brown GR, de Vries ALC, Deutsch MB, Ettner R, Fraser L, Goodman M, Green J, Hancock AB, Johnson TW, Karasic DH, Knudson GA, Leibowitz SF, Meyer-Bahlburg HFL, Monstrey SJ, Motmans J, Nahata L, Nieder TO, Reisner SL, Richards C, Schechter LS, Tangpricha V, Tishelman AC, Van Trotsenburg MAA, Winter S, Ducheny K, Adams NJ, Adrián TM, Allen LR, Azul D, Bagga H, Başar K, Bathory DS, Belinky JJ, Berg DR, Berli JU, Bluebond-Langner RO, Bouman MB, Bowers ML, Brassard PJ, Byrne J, Capitán L, Cargill CJ, Carswell JM, Chang SC, Chelvakumar G, Corneil T, Dalke KB, De Cuypere G, de Vries E, Den Heijer M, Devor AH, Dhejne C, D'Marco A, Edmiston EK, Edwards-Leeper L, Ehrbar R, Ehrensaft D, Eisfeld J, Elaut E, Erickson-Schroth L, Feldman JL, Fisher AD, Garcia MM, Gijs L, Green SE, Hall BP, Hardy TLD, Irwig MS, Jacobs LA, Janssen AC, Johnson K, Klink DT, Kreukels BPC, Kuper LE, Kvach EJ, Malouf MA, Massey R, Mazur T, McLachlan C, Morrison SD, Mosser SW, Neira PM, Nygren U, Oates JM, Obedin-Maliver J, Pagkalos G, Patton J, Phanuphak N, Rachlin K, Reed T, Rider GN, Ristori J, Robbins-Cherry S, Roberts SA, Rodriguez-Wallberg KA, Rosenthal SM, Sabir K, Safer JD, Silva AB, Spencer K, St Amand C, Steensma TD, Strang JF, Taylor GB, Tilleman K, Tolentino TF, Vermeir E, Vlot M, Whelan E, Zwickl S. Standards of Care for the Health of Transgender and Gender Diverse People, Version 8. International Journal of Transgender Health. 2022. PMID 36238954. (accessed 2026-05-11)
  40. [files2011bioidentical] Files JA, Ko MG, Pruthi S. Bioidentical hormone therapy. Mayo Clinic Proceedings. 2011. PMID 21531972. (accessed 2026-05-11)
  41. [boardman2015cochranecv] Boardman HM, Hartley L, Eisinga A, Main C, Roqué i Figuls M, Bonfill Cosp X, Gabriel Sanchez R, Knight B. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database of Systematic Reviews. 2015. PMID 25754617. (accessed 2026-05-11)
  42. [marjoribanks2018cochrane] Marjoribanks J, Farquhar C, Roberts H, Lethaby A, Lee J. Cochrane corner: long-term hormone therapy for perimenopausal and postmenopausal women. Heart. 2018. PMID 28739806. (accessed 2026-05-11)
  43. [nasem2020] Committee on the Clinical Utility of Treating Patients with Compounded Bioidentical Hormone Replacement Therapy; National Academies of Sciences, Engineering, and Medicine. The Clinical Utility of Compounded Bioidentical Hormone Therapy: A Review of the Evidence. National Academies Press. 2020. https://nap.nationalacademies.org/catalog/25791/the-clinical-utility-of-compounded-bioidentical-hormone-therapy-a-review (accessed 2026-05-11)
  44. [fda_essentially_a_copy] U.S. Food and Drug Administration. Compounded Drug Products That Are Essentially Copies of Approved Drug Products Under Section 503A of the Federal Food, Drug, and Cosmetic Act — Guidance for Industry. FDA Guidance for Industry. 2018. https://www.fda.gov/media/98973/download (accessed 2026-05-11)
  45. [usp_795] United States Pharmacopeia. USP General Chapter <795> Pharmaceutical Compounding — Nonsterile Preparations. USP Compounding Compendium. 2024. https://www.usp.org/compounding/general-chapter-795 (accessed 2026-05-11)
  46. [usp_797] United States Pharmacopeia. USP General Chapter <797> Pharmaceutical Compounding — Sterile Preparations. USP Compounding Compendium. 2024. https://www.usp.org/compounding/general-chapter-797 (accessed 2026-05-11)

How to access

How to Access Estradiol

Compounded Estradiol is dispensed under 503A on a patient-specific prescription. Pick the path that matches where you're starting from.

For doctors

Offer this medication.

A pharmacist will follow up within two business days. We'll cover state availability, supported formulations, and what integration looks like for your clinic.

Offer this medication →

Patient with a doctor

Receive your prescription.

If your doctor has already prescribed Estradiol, sign up so we can prepare and ship your medication. The signup wizard collects intake and connects you to the prescribing workflow.

Sign up →

Patient without a doctor

Find a partner clinic.

RonanRx prescribes through partner clinics — we don't initiate prescriptions on this site. See how the referral works and how to find a clinic in your state that has evaluated patients for Estradiol.

Find a partner clinic →

Related